CareDx (CDNA) | Financial Analysis & Statements
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
333.8M
Gross Profit
224.2M
67.16%
Operating Income
-53.8M
-16.10%
Net Income
52.5M
15.74%
EPS (Diluted)
$0.93
Balance Sheet Metrics
Total Assets
491.0M
Total Liabilities
112.6M
Shareholders Equity
378.4M
Debt to Equity
0.30
Cash Flow Metrics
Operating Cash Flow
113.7M
Free Cash Flow
31.6M
Revenue & Profitability Trend
CareDx Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 333.8M | 280.3M | 321.8M | 296.4M | 192.2M |
| Cost of Goods Sold | 109.6M | 102.0M | 112.2M | 97.4M | 63.1M |
| Gross Profit | 224.2M | 178.3M | 209.6M | 199.0M | 129.1M |
| Operating Expenses | 277.9M | 283.1M | 286.8M | 228.7M | 146.8M |
| Operating Income | -53.8M | -104.7M | -77.2M | -29.7M | -17.7M |
| Pre-tax Income | 52.9M | -190.1M | -76.2M | -32.1M | -19.8M |
| Income Tax | 310.0K | 141.0K | 379.0K | -1.4M | -1.0M |
| Net Income | 52.5M | -190.3M | -76.6M | -30.7M | -18.7M |
| EPS (Diluted) | $0.93 | -$3.54 | -$1.44 | -$0.59 | -$0.40 |
Income Statement Trend
CareDx Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 351.8M | 313.7M | 387.8M | 433.4M | 273.1M |
| Non-Current Assets | 139.2M | 153.1M | 155.1M | 133.3M | 95.4M |
| Total Assets | 491.0M | 466.8M | 543.0M | 566.6M | 368.5M |
| Liabilities | |||||
| Current Liabilities | 89.4M | 78.1M | 76.0M | 77.3M | 69.2M |
| Non-Current Liabilities | 23.2M | 127.4M | 36.1M | 23.4M | 21.6M |
| Total Liabilities | 112.6M | 205.5M | 112.1M | 100.7M | 90.8M |
| Equity | |||||
| Total Shareholders Equity | 378.4M | 261.3M | 430.9M | 465.9M | 277.7M |
Balance Sheet Composition
CareDx Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 52.5M | -190.3M | -76.6M | -30.7M | -18.7M |
| Operating Cash Flow | 113.7M | -111.6M | -28.2M | -36.4M | 23.3M |
| Investing Activities | |||||
| Capital Expenditures | - | - | - | - | - |
| Investing Cash Flow | 6.0M | 49.7M | -204.2M | 68.0M | -90.0M |
| Financing Activities | |||||
| Dividends Paid | - | - | - | - | - |
| Financing Cash Flow | -15.9M | -31.2M | -9.2M | 170.7M | 153.4M |
| Free Cash Flow | 31.6M | -27.6M | -49.6M | -39.6M | 23.1M |
Cash Flow Trend
CareDx Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
16.92
Forward P/E
32.67
Price to Book
2.77
Price to Sales
3.05
PEG Ratio
32.67
Profitability Ratios
Profit Margin
17.92%
Operating Margin
-9.46%
Return on Equity
19.54%
Return on Assets
-5.20%
Financial Health
Current Ratio
4.11
Debt to Equity
7.98
Beta
2.18
Per Share Data
EPS (TTM)
$1.12
Book Value per Share
$6.84
Revenue per Share
$6.46
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| cdna | 1.1B | 16.92 | 2.77 | 19.54% | 17.92% | 7.98 |
| Thermo Fisher | 152.5B | 23.69 | 3.09 | 13.70% | 15.19% | 69.23 |
| Danaher | 140.5B | 37.98 | 2.76 | 7.22% | 15.81% | 34.56 |
| Twist Bioscience | 2.2B | -9.85 | 4.89 | -38.22% | -54.98% | 18.25 |
| Grail | 1.5B | -0.70 | 0.61 | -62.22% | -62.12% | 2.67 |
| Opko Health | 1.0B | -16.12 | 0.65 | -3.04% | -5.66% | 37.58 |
Financial data is updated regularly. All figures are in the company's reporting currency.